Pierre Dellamonica

Author PubWeight™ 66.93‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007 3.38
2 Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006 2.19
3 Factors associated with adherence to infectious diseases advice in two intensive care units. J Antimicrob Chemother 2006 2.04
4 The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008 1.76
5 Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009 1.65
6 Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004 1.64
7 Bacteremia in patients receiving TNF-alpha antagonists--a prospective multicenter study. J Infect 2013 1.52
8 Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial. Basic Clin Pharmacol Toxicol 2011 1.42
9 Scalp eschar and neck lymphadenopathy caused by Bartonella henselae after Tick Bite. Clin Infect Dis 2010 1.40
10 Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data. J Antimicrob Chemother 2009 1.39
11 [Value of PCR amplification from formalin-fixed paraffin-embedded tissues in the diagnosis of Mycobacterium tuberculosis infection]. Ann Pathol 2003 1.36
12 Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials 2003 1.36
13 Risk factors of chronic kidney disease in HIV-infected patients. Clin J Am Soc Nephrol 2011 1.21
14 Health related quality of life among both current and former injection drug users who are HIV-infected. Drug Alcohol Depend 2006 1.18
15 Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy. Antimicrob Agents Chemother 2009 1.17
16 Severe pneumonia during primary infection with an atypical strain of Toxoplasma gondii in an immunocompetent young man. J Infect 2005 1.16
17 PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002 1.15
18 Self-reported fatigue and depressive symptoms as main indicators of the quality of life (QOL) of patients living with HIV and Hepatitis C: implications for clinical management and future research. HIV Clin Trials 2007 1.14
19 Influence of child care on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae. Pediatr Infect Dis J 2003 1.14
20 Haemophilus influenzae carriage in children attending French day care centers: a molecular epidemiological study. J Clin Microbiol 2003 1.05
21 Uncontrolled viral replication as a risk factor for non-AIDS severe clinical events in HIV-infected patients on long-term antiretroviral therapy: APROCO/COPILOTE (ANRS CO8) cohort study. J Acquir Immune Defic Syndr 2009 1.00
22 Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders? AIDS 2014 0.99
23 Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study. Arthritis Res Ther 2010 0.96
24 [Tuberculosis: a rare and misleading etiology of tongue's ulcer]. Ann Pathol 2003 0.95
25 Trends in nasopharyngeal carriage of Streptococcus pneumoniae among children attending daycare centers in southeastern France from 1999 to 2006. Pediatr Infect Dis J 2008 0.95
26 Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis 2005 0.93
27 Evaluation of e-Bug, an educational pack, teaching about prudent antibiotic use and hygiene, in the Czech Republic, France and England. J Antimicrob Chemother 2010 0.93
28 A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Antivir Ther 2006 0.90
29 Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother 2006 0.90
30 Adding HCV treatment to HIV treatment in HIV-HCV coinfected patients: the impact on the different dimensions of fatigue and self-reported side effects. J Pain Symptom Manage 2007 0.84
31 Lopinavir/ritonavir combination and total/HDL cholesterol ratio. J Infect 2005 0.84
32 The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review. Virol J 2012 0.83
33 Hand edema and acrocyanosis: "puffy hand syndrome". Arch Dermatol 2006 0.83
34 Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study. Chest 2013 0.83
35 Sensitive enzyme immunoassay for measuring plasma and intracellular nevirapine levels in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004 0.82
36 Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients? AIDS Rev 2008 0.82
37 Kinetics of disappearance of resistance mutations and reappearance of wild-type during structured treatment interruptions. AIDS 2003 0.82
38 The e-Bug project in France. J Antimicrob Chemother 2011 0.82
39 Early CD4(+) T cell recovery in human immunodeficiency virus-infected patients receiving effective therapy is related to a down-regulation of apoptosis and not to proliferation. J Infect Dis 2002 0.82
40 The value of polymerase chain reaction detection of Mycobacterium tuberculosis in granulomas isolated by laser capture microdissection. Pathology 2004 0.81
41 Sarcoid-like lesions associated with the immune restoration inflammatory syndrome in AIDS: absence of polymerase chain reaction detection of Mycobacterium tuberculosis in granulomas isolated by laser capture microdissection. Virchows Arch 2006 0.81
42 Pseudomonas aeruginosa ecthyma gangrenosum and facial cellulitis complicating carbimazole-induced agranulocytosis. Arch Dermatol 2006 0.81
43 Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort. Ther Drug Monit 2005 0.81
44 Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects. J Acquir Immune Defic Syndr 2013 0.81
45 Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE. Clin Infect Dis 2009 0.80
46 Baseline CD4 cell count and outcome of pegylated interferon plus ribavirin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2008 0.79
47 Concomitant Staphylococcus aureus bacteriuria is associated with complicated S. aureus bacteremia. J Infect 2009 0.78
48 HIV-1 infection and first line ART induced differential responses in mitochondria from blood lymphocytes and monocytes: the ANRS EP45 "Aging" study. PLoS One 2012 0.78
49 Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. J Neurovirol 2013 0.78
50 An enzyme immunoassay for the quantification of plasma and intracellular lopinavir in HIV-infected patients. J Immunol Methods 2004 0.78
51 HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study. PLoS One 2012 0.78
52 Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study. Addiction 2010 0.78
53 In vivo comparative pharmacokinetics and pharmacodynamics of moxifloxacin and levofloxacin in human neutrophils. Clin Drug Investig 2005 0.78
54 Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART). Drug Alcohol Depend 2008 0.78
55 HIV-1 and persistent clinical latency, TAR element analysis and improved method for in vitro viral reactivation. J Clin Virol 2007 0.77
56 Fluoroquinolone prescriptions in a teaching hospital: a prospective audit. Scand J Infect Dis 2007 0.77
57 Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial. Antivir Ther 2008 0.77
58 Impaired anger control as an underappreciated side effect of treatments for chronic HCV infection in HIV-HCV coinfected patients. J Clin Gastroenterol 2008 0.77
59 Yeast cells as a tool for analysis of HIV-1 protease susceptibility to protease inhibitors, a comparative study. J Virol Methods 2013 0.77
60 ["Antibiotics only when necessary" campaign in the Alpes-Maritimes district: no negative impact on invasive infections in children in the community 1998-2003]. Presse Med 2008 0.77
61 Infliximab and human immunodeficiency virus infection: Viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med 2006 0.77
62 Factors associated with liver biopsy performance in HCV-HIV coinfected injecting drug users with HCV viremia: results from a five-year longitudinal assessment. J Urban Health 2004 0.76
63 Apoptosis of naive CD4+ T-cells from HIV-infected patients with poor immune response to HAART is enhanced in vitro by steroid. J Infect 2004 0.76
64 First-line cART regimen impacts the course of CD8+ T-cell counts in HIV-infected patients that achieve sustained undetectable viral load. Medicine (Baltimore) 2016 0.75
65 Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine. Antimicrob Agents Chemother 2004 0.75
66 Influenza vaccination: impact of an intervention campaign targeting hospital staff. Infect Control Hosp Epidemiol 2006 0.75
67 [Antiretroviral treatments-related lipodystrophy syndrome: clinico-pathological findings]. Ann Pathol 2005 0.75
68 [An oral infection not to be underestimated: actinomycosis. A study of 4 cases with extensive bone necrosis]. Ann Pathol 2003 0.75
69 Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohort. Scand J Infect Dis 2011 0.75
70 Cutaneous complications of direct intra-arterial injections in drug addicts. Acta Derm Venereol 2005 0.75
71 [Peer visits to community-based general practitioners and pediatricians as part of the "Antibiotics only when necessary" campaign in the Alpes-Maritimes district. Methodology, feasibility, and interest]. Presse Med 2006 0.75
72 [Escherichia coli bacteremic urinary tract infections. Clinical aspects and pronostic factors]. Presse Med 2004 0.75
73 [Registry of liver biopsies from hepatitis C infected patients in the Alpes-Maritimes (France). Results from the first 2 years]. Gastroenterol Clin Biol 2002 0.75
74 What do HIV-infected patients become after an opportunistic infection? AIDS 2006 0.75
75 Neuromeningeal tuberculosis in a patient with rheumatoid arthritis previously exposed to ineffective etanercept therapy and revealed by infliximab. J Rheumatol 2010 0.75
76 Apoptosis and proliferation kinetics of T cells in patients having experienced antiretroviral treatment interruptions. J Antimicrob Chemother 2003 0.75
77 Long-term virological outcome in patients infected with multi-nucleoside analogue-resistant HIV-1. Antivir Ther 2002 0.75
78 Epidemiology of autoimmune and inflammatory diseases in a French Nationwide HIV cohort. AIDS 2017 0.75